ARTICLE | Finance
Going big in Europe
Why Arch's Carrick investment is the opposite of how it usually forms newcos
October 10, 2016 7:00 AM UTC
Arch Venture's biggest investment to date in Europe is also the complete opposite of how the firm normally starts biotech companies. Arch is co-leading a tranched $95 million series A round for Carrick Therapeutics Ltd. with the expectation the company's management will be able to amass multiple first-in-class therapies for aggressive, resistant forms of cancer.
Typically, Arch likes to find a fledgling platform and put it through its paces before making a massive investment. In addition, the investment usually is supplemented by non-dilutive dollars from partnerships and government grants. ...